4.77% 0.00105

Syros Pharmaceuticals Inc (SYRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Syros Pharmaceuticals Inc

Healthcare (1174)

Biotechnology (662)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SYRS's Discussions on Twitter

Vergleichen Sie SYRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SYRS Syros Pharmaceuticals Inc	0.0231	0	9.94M	-144.49M	-103.90M	-5.05
VRTX Vertex Pharmaceuticals Inc	442.87	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	511.21	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	313.17	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	540.25	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	258.17	28.51B	3.81B	-644.79M	-669.77M	-6.24

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-11-04	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-09-22	Eingeleitet	Alliance Global Partners	Buy
2020-01-17	Herabstufung	Wedbush	Outperform → Neutral
2019-03-08	Fortgesetzt	JMP Securities	Mkt Outperform
2019-02-14	Fortgesetzt	Oppenheimer	Outperform
2018-11-05	Hochstufung	ROTH Capital	Neutral → Buy
2018-03-13	Bestätigt	Wedbush	Outperform
2017-10-31	Fortgesetzt	Piper Jaffray	Overweight
2017-10-23	Eingeleitet	ROTH Capital	Neutral
2017-08-10	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform

Alle ansehen

Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten

Finanzdaten der Syros Pharmaceuticals Inc-Aktie (SYRS)

Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Vergleichen Sie SYRS mit anderen Aktien

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten

Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities LawsSYRS - ACCESS Newswire

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World

SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Press Release Distribution & PR Platform - ACCESS Newswire

Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire

SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire

StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN

Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co

Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan

Syros Pharma pulls out of deal with RaQualia - The Pharma Letter

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World

Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India

Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga

Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga

Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa

Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India

Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga

Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com

Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com

Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch

Syros to delist from Nasdaq, deregister from SEC - MSN

Finanzdaten der Syros Pharmaceuticals Inc-Aktie (SYRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SYRS